drugset / Trial / NCT07311330

Phase IIa Clinical Trial of YN001 in Patients With Atherosclerotic Cardiovascular and Cerebrovascular Diseases and Erectile Dysfunction

NCT07311330 ↗

Phase 2 Recruiting 40 enrolled Beijing Inno Medicine Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a randomized, double-blind, placebo-controlled phase IIa clinical trial to evaluate the efficacy and safety of YN001 in patients with atherosclerotic cardiovascular and cerebrovascular diseases and erectile dysfunction

Timeline

Start
2026-02-04
Primary completion
2026-10
Completion
2026-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator YN001 Unknown 20 mg —